[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628268":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":24,"responsibleParty":41,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Guven Health Group","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment-Naïve Chronic HBV Patients",null,"Adult (≥18 years) HBsAg-positive patients with HBV-DNA \\>2,000 IU\u002FmL who have not received prior nucleos(t)ide analogue therapy.",[13],"Diagnostic Test: Viral genetic material from blood samples using advanced sequencing technology",{"label":15,"type":10,"description":16,"interventionNames":17},"Lamivudine-Experienced Chronic HBV Patients","Adult (≥18 years) HBsAg-positive patients with a documented history of lamivudine therapy for ≥6 months who were subsequently switched to tenofovir-based therapy (ADV, TDF, or TAF) and have not received entecavir or telbivudine.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Viral genetic material from blood samples using advanced sequencing technology","No intervention",[15,9],[25],{"facility":26,"status":10,"city":27,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Gaziantep University","Gaziantep","Turkey (Türkiye)",{"type":30,"coordinates":31},"Point",[32,33],37.3825,37.05944,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Ayşe Özlem Mete, MD","CONTACT","+905064883309","ayseozlem_ornek@hotmail.com",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Yaşar Bayındır, MD","Chief Physican",[46],{"name":47,"class":48},"SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY","UNKNOWN","100628268","entecavir-resistance-associated-mutations-in-chronic-hbv-patients-in-turkey-stream-study-100628268",false,"NCT07459426","Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","Sequencing-Based Tracking of Entecavir Resistance-Associated Mutations in Chronic Hepatitis B Patients: A Multicenter Observational Study (STREAM)","Inclusion Criteria:\n\n* Age ≥18 years\n* HBsAg positive\n* Group 1: Either treatment-naïve participants with HBV DNA\\>2000 IU\u002Fml\n* Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior entecavir exposure\n* Prior telbivudine exposure\n* Age \\\u003C18 years\n* Inability to provide informed consent Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion.\n\nPatients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.","ALL","18 Years","80 Years",{"count":60,"type":61},700,"ESTIMATED","OBSERVATIONAL","Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.\n\nSome older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations.\n\nBy analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.",[65],"Hepatitis B, Chronic",[67,68,69,70],"Chronic hepatitis B","Lamivudine","Entecavir","Antiviral resistance","NOT_YET_RECRUITING","2026-03-05",{"date":74,"type":75},"2026-03-09","ACTUAL",{"date":77,"type":61},"2026-03-15",{"date":79,"type":61},"2027-03-15",{"name":43,"class":6},1]